Minute Insight: Abbott’s Libre 3 Finds Route To NHS Patients With YpsoMed And CamDiab Partnership
Executive Summary
Abbott’s flagship CGM, the FreeStyle Libre 3, will soon become available in the UK through the National Health Service as part of a hybrid closed-loop system utilizing Ypsomed and CamDiab’s technologies.
You may also be interested in...
Medtronic’s 780G – Finally! – Gets FDA Approval
Earlier than expected, but still after a more than three year wait, the company has obtained FDA approval for its flagship insulin delivery system.
UK To Fund ‘Artificial Pancreas’ Technology, But Only For Companies That Cut Prices
The UK’s health technology assessment organization is in favor of funding hybrid closed loop systems for certain people with type 1 diabetes, but only if companies agree to provide such products at more “cost-effective” prices.
Exec Chat: PacBio Addresses Latest Results, New Tech And Long-Read Sequencing’s Future
PacBio has been burning through investors’ cash as it works to make long-read sequencing more accessible. Neil Ward, the company’s general manager, laid out his thoughts on the technology, its place in the market and how genomics data can be both effectively and fairly utilized.